An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, Solbach C, Diebold K, Marme F, Müller V, Schneeweiss A, Sinn HP, Fehm T, Schem C, Stickeler E, Fasching PA, Budczies J, Felder B, Nekljudova V, Holtschmidt J, Untch M, Denkert C, Loibl S.
Jank P, et al. Among authors: lindner j.
Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38837894